Lindsay Machen, MD
Ophthalmology · Langhorne, PANPI 1649667452
Payments from drug & device makers
Across 93 payments — averaging $64.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$1K
- AbbVie$826
- Sight Sciences, Inc.$591
- Aerie Pharmaceuticals, Inc.$296
- Iridex Corporation$255
- plus $956 from 15 others
What the payments were for
- Food & beverage$5,971100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $1,748 |
| Glaukos Corporation | 12 | $1,300 |
| AbbVie(2 entities) | 24 | $826 |
| Sight Sciences, Inc. | 9 | $591 |
| Aerie Pharmaceuticals, Inc. | 6 | $296 |
| Iridex Corporation | 1 | $255 |
| NEW World Medical,inc. | 1 | $159 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Ivantis, Inc | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $124 |
| Ellexiscience | 1 | $106 |
| Novartis | 3 | $77 |
| Bausch & Lomb Americas Inc. | 2 | $45 |
| Ocular Therapeutix, Inc. | 2 | $42 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Akorn, Inc. | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,108
- iStent inject W$297
- OMNI$217
- Kahook Dual Blade$159
- Streamline Surgical System$159
- Ahmed Glaucoma Valve$159
- iStent infinite Trabecular Micro-Bypass System Model iS3$148
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$148
- ARGOS$145
- OMNI(R) SURGICAL SYSTEM (US)$139
- Hydrus Microstent$132
- Photrexa$125
- XEN$125
- Tecnis Symfony IOL$125
- Hydrus$125
- iStent Trabecular Micro-Bypass Stent System$121
- iStent inject Trabecular Micro-Bypass Stent System$121
- Rhopressa$118
- Rocklatan$118
- XEN GLAUCOMA TREATMENT SYSTEM$117
How this compares
$5,971 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 220 | $120,714 |
| RocklatanNetarsudil Mesylat/Latanoprost | 80 | $42,902 |
| RhopressaNetarsudil Mesylate | 89 | $42,623 |
| XiidraLifitegrast | 27 | $37,292 |
| Latanoprost | 2,976 | $34,687 |
| Prednisolone Acetate | 677 | $29,969 |
| RestasisCyclosporine | 26 | $28,078 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,668 | $27,786 |
| Brimonidine Tartrate | 1,013 | $24,096 |
| VyzultaLatanoprostene Bunod | 43 | $23,581 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 81 | $21,895 |
| Cyclosporine | 50 | $20,621 |
| Travoprost | 123 | $18,633 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 75 | $17,082 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $11,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $826 | $167,172290 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $296 | $85,525169 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $45 | $60,87270 claims |
| AlconSimbrinza, Azopt | $1,748 | $28,91599 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Langhorne
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.